Literature DB >> 11202051

Porphyrins, porphyrin metabolism and porphyrias. IV. Pathophysiology of erythyropoietic protoporphyria--diagnosis, care and monitoring of the patient.

S Thunell1, P Harper, A Brun.   

Abstract

An extremely painful cutaneous condition with no or only slight visible skin changes, presenting in a child or an adult as an acute reaction to sun light, is probably a manifestation of the porphyrin metabolic disorder erythropoietic protoporphyria (EPP). The disease is the result of a genetically determined condition where a mutation in the gene for the final enzyme in the haem synthetic chain, ferrochelatase, results in impaired activity of the enzyme. In some predisposed individuals, the condition is accompanied by heavy accumulation of the substrate for the deficient enzyme, i.e. of protoporphyrin. Distributing to the skin, and there absorbing light of certain wavelengths, the metabolite generates free radicals that give rise to photodynamic cell injury. The primary event takes place in the endothelial cells of the superficial skin capillaries, but complement activation and mast cell degranulation in the surrounding tissue follow in the process. Even if the disease is primarily dermatological the hepatic and psychosocial complications are features requiring close attention by the physician. In order to provide a basis for suggestions regarding lege artis protocols for the diagnosis, treatment and monitoring of the patient with EPP, the pathophysiology of the cutaneous and hepatic manifestations are discussed in some detail in the article.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11202051

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  19 in total

1.  Pro-oxidant and antioxidant factors in acute intermittent porphyria: family studies.

Authors:  E Rocchi; P Ventura; A Ronzoni; M C Rosa; C Gozzi; L Marri; G Casalgrandi; M D Cappellini
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 2.  [Erythropoietic protoporphyria : Clinical manifestations, diagnosis and new therapeutic possibilities].

Authors:  U Urbanski; J Frank; N J Neumann
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

Review 3.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 4.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Gut       Date:  2007-03-14       Impact factor: 23.059

5.  Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria.

Authors:  Pauline Harper; Staffan Wahlin
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

6.  Paralytic ileus and liver failure--an unusual presentation of advanced erythropoietic protoporphyria.

Authors:  Simone Negrini; Gabriele Zoppoli; Maurizio Setti; Maria Domenica Cappellini; Francesco Indiveri
Journal:  Dig Dis Sci       Date:  2008-11-14       Impact factor: 3.199

7.  [Erythropoietic protoporphyria. A rare differential diagnosis among photosensitive diseases].

Authors:  C Schiekofer; T Vogt; J Reichrath
Journal:  Hautarzt       Date:  2012-12       Impact factor: 0.751

8.  Production and characterization of erythropoietic protoporphyric heterodimeric ferrochelatases.

Authors:  Wided Najahi-Missaoui; Harry A Dailey
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

Review 9.  Pain associated with aminolevulinic acid-photodynamic therapy of skin disease.

Authors:  Christine B Warren; Laszlo J Karai; Allison Vidimos; Edward V Maytin
Journal:  J Am Acad Dermatol       Date:  2009-12       Impact factor: 11.527

Review 10.  Erythropoietic protoporphyria.

Authors:  Mario Lecha; Hervé Puy; Jean-Charles Deybach
Journal:  Orphanet J Rare Dis       Date:  2009-09-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.